Invesaro

Stocks Health care PGNY

NASDAQ · Health care

Progyny, Inc. (PGNY)

Progyny, Inc. brought in $1.3B of revenue over the twelve months to June 30, 2026, up 5.5% from a year earlier. Net income was $78.6M, a net margin of 6.0%. Operating cash flow minus capital spending left $191.8M of free cash flow in fiscal 2025. At June 30, 2026 it held $152.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Price
$25.44
-2.04% on the day · September 25, 2026
52-week range $16.10 to $33.07
Market cap
$2B
Revenue (last 12 months)
$1.3B
+5.5% year on year
Net margin
6.0%
P/E
39.1
on FY2025 diluted EPS

What Progyny, Inc. does

Progyny, Inc. is registered with the SEC under industry code SIC 8090 (Services-Misc Health & Allied Services, NEC). Its shares trade on NASDAQ under the ticker PGNY.

Revenue and profit by year

Revenue
FY19: $105.4M $105.4M FY19FY19: $229.7M $229.7M FY19FY20: $344.9M $344.9M FY20FY21: $500.6M $500.6M FY21FY22: $786.9M $786.9M FY22FY23: $1.1B $1.1B FY23FY24: $1.2B $1.2B FY24FY25: $1.3B $1.3B FY25
Net income
FY19: $661K $661K FY19FY19: -$8.6M -$8.6M FY19FY20: $46.5M $46.5M FY20FY21: $65.8M $65.8M FY21FY22: $30.4M $30.4M FY22FY23: $62M $62M FY23FY24: $54.3M $54.3M FY24FY25: $58.5M $58.5M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$1.3B$85.3M$58.5M$0.65$191.8M
2024$1.2B$67.5M$54.3M$0.57$173.7M
2023$1.1B$62.2M$62M$0.62$185.2M
2022$786.9M$23.3M$30.4M$0.30$77.2M
2021$500.6M$32.3M$65.8M$0.66$23.9M
2020$344.9M$8.3M$46.5M$0.47$35.2M
Next report expected around November 5, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 6, 2025. Not a date the company has announced. See the report calendar

Where PGNY ranks in Health care

Revenue$1.3B
#133 of 523 in Health care · Top 25%
Revenue growth+10.4%
#242 of 437 in Health care · Bottom 45%
Net margin4.5%
#146 of 447 in Health care · Top 33%
Free cash flow margin14.9%
#78 of 408 in Health care · Top 19%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Progyny, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 7, 2026
    Quarterly report 10-Q · period to June 30, 2026
  2. August 6, 2026
    Quarterly results 8-K
  3. August 6, 2026
    Passive stake changed SCHEDULE 13G/A
  4. June 8, 2026
    Passive stake changed SCHEDULE 13G/A
  5. May 27, 2026
    Bylaws or fiscal year changed 8-K
  6. May 26, 2026
    Other event 8-K
  7. May 8, 2026
    Quarterly report 10-Q · period to March 31, 2026
  8. May 7, 2026
    Quarterly results 8-K
  9. April 29, 2026
    Passive stake (5% or more) SCHEDULE 13G
  10. April 10, 2026
    Annual report to shareholders ARS

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 23, 2026. Insider transactions on SEC

What is PGNY worth? A DCF from its reported cash flow

Insider trades

What the people running Progyny, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $633.2K worth of shares in the last 90 days and bought none on the open market.

Bought (open market)
$0
last 90 days
Sold
$633.2K
last 90 days
Net sold
23,000
$633.2K
DateInsiderWhatSharesPriceValueFiling
September 17, 2026 Clapp GeoffreyChief Product Officer Shares withheld for tax 819 $27.38 $22.4K Form 4
September 10, 2026 Gordon Kevin KDirector Exercised options 22,000 $13.00 $286K Form 4
September 10, 2026 Gordon Kevin KDirector Shares withheld for tax 10,500 $27.24 $286K Form 4
September 10, 2026 Gordon Kevin KDirector Sold 11,500 $27.12 $311.9K Form 4
September 10, 2026 Gordon Kevin KDirector Exercised options 22,000 $13.00 $286K Form 4
September 10, 2026 Gordon Kevin KDirector Shares withheld for tax 10,500 $27.24 $286K Form 4
September 10, 2026 Gordon Kevin KDirector Sold 11,500 $27.94 $321.4K Form 4
September 4, 2026 Livingston Mark S.CHIEF FINANCIAL OFFICER Shares withheld for tax 479 $26.61 $12.7K Form 4
September 4, 2026 Swartz AllisonEVP, GC Shares withheld for tax 479 $26.61 $12.7K Form 4
September 3, 2026 Swartz AllisonEVP, GC Shares withheld for tax 828 $26.29 $21.8K Form 4
September 3, 2026 Anevski PeterCHIEF EXECUTIVE OFFICER, Director Shares withheld for tax 5,361 $26.29 $140.9K Form 4
September 3, 2026 Livingston Mark S.CHIEF FINANCIAL OFFICER Shares withheld for tax 1,532 $26.29 $40.3K Form 4
September 2, 2026 Livingston Mark S.CHIEF FINANCIAL OFFICER Shares withheld for tax 224 $25.66 $5.7K Form 4
August 28, 2026 Swartz AllisonEVP, GC Shares withheld for tax 1,352 $25.86 $35K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about PGNY

What does Progyny, Inc. do?

Progyny, Inc. is registered with the SEC under industry code SIC 8090 (Services-Misc Health & Allied Services, NEC). Its shares trade on NASDAQ under the ticker PGNY.

Is Progyny, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $78.6M on revenue of $1.3B, a net margin of 6.0%.

How much revenue does Progyny, Inc. make?

Over the twelve months to June 30, 2026 Progyny, Inc. reported revenue of $1.3B. That is 5.5% more than a year earlier.

When did Progyny, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 23, 2026.

Similar companies

DVA
Davita Inc.
AGL
agilon health, inc.
SHC
Sotera Health Co
VMD
Viemed Healthcare, Inc.
PARK
Park Dental Partners, Inc.
PCAI
Powercheck AI Holdings Ltd

Compare PGNY with

PGNYvsDVA
Davita
PGNYvsAGL
agilon health
PGNYvsSHC
Sotera Health
PGNYvsVMD
Viemed Healthcare

Compare PGNY with any company

Follow PGNY

Get an email when Progyny, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PGNY: get an email when it files

Where the numbers come from

Financial figures are the values Progyny, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.